Ophthalmology

Age-related macular degeneration is the most common cause of vision loss in adults over age 50, but there are few treatments available. Researchers are now developing promising stem cell therapies to treat the disease.

Researchers are developing gene and cell therapies and prosthetics to help patients with blindness regain some vision. The first major prosthetic, the Argus II, was just discontinued. Where will the field go from here?

Between invasive surgery or risky laser therapy, people suffering from severe eye floaters have no great treatment options. Now, with the development of a safer and less invasive nanoparticle-based therapy, people with floaters may finally get their vision and quality of life back.

Researchers pioneered a new strategy for diagnosing puzzling genetic diseases, expanding scientists’ capability to study their causes and pathophysiology.

Scientists identify a new target for treating age-related eye diseases

ABIONYX achieves positive clinical results with CER-001 in familial lecithin–cholesterol acyltransferase deficiency

Data show full complement ST266 biologic offers better neuroprotection than fractionated formats

Roche's faricimab injected every 16 weeks proves non-inferior to aflibercept injected every eight weeks in patients with “wet” age-related macular degeneration

The acquisition includes clinical stage anti-IGF-1R monoclonal antibody VRDN-001, which is intended for treatment of thyroid eye disease

Vanda Pharmaceuticals gains FDA approval on their IND for VSJ-110 to treat allergic conjunctivitis

Astrocytes could play a critical role in nerve death in neurodegenerative diseases